Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase II trials, the Company is seeking to

In addition to ORMD-0801, Oramed’s pipeline consists of an oral method for the delivery of GLP1-Analog (OMRD-0901), which is currently in Phase 1 clinical trials. Oramed’s unique oral delivery technology can further serve as a platform for other peptides.

Oramed's breakthroughs have earned the company the support of Professor Avram Hershko, Professor John Amatruda, Professor Ele Ferrannini, Professor Barzilai, and Professor LeRoith, who have each joined its scientific advisory Board. Oramed has also earned the acclaim of the broader scientific community: publications regarding the clinical development of Oramed's platform technology have been presented at international conferences such as those of the ADA, the EASD, and Diabetes Technology.

Technology

Based on extensive research in polypeptide drug delivery, Oramed has developed a proprietary technology for the oral administration of a variety of peptides beyond insulin.   The technology facilitates the passage of peptides into the bloodstream, bypassing the digestive system, thereby overcoming the obstacle of oral peptide delivery.

Contact Details
Address:  Kefar Hi-tech 2/5 Givat Ram P.O. Box 39098 Jerusalem 91390
Phone: 02-566-0001
Fax : 02-566-0004
Email:  Tara@oramed.com         
Internet Site: www.oramed.com

Exhibition Representative
Name: Nadav Kidron
Mobile: 1-917-355-2101
E-mail: Nadav@oramed.com

Category: Biotechnology